KMDAHealthcare · Drug Manufacturers - Specialty & GenericThe 3 Wall Street analysts covering Kamada Ltd. hold a median 12-month price target of $14 — +78.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 9 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Kamada Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (45): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on KMDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +78.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | $11 → $13 |
| 15 May 2025 | Benchmark | Reiterates | Buy | — |
| 21 Mar 2025 | Benchmark | Initiates | Buy | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 July 2024 | Stifel | Initiates | Buy | — |
| 9 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Feb 2018 | Chardan Capital | Initiates | Buy | — |
| 13 Nov 2015 | Jefferies | Maintains | Buy | — |
| 25 June 2013 | Jefferies | Initiates | Buy | — |
| 25 June 2013 | Morgan Stanley | Initiates | Equal-Weight | — |
| 25 June 2013 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KMDA appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, Kamada Ltd. returned +21.0% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 37% of US stocks
Cheaper than 47% of US stocks
Cheaper than 49% of US stocks
Cheaper than 39% of US stocks
Higher than 72% of US stocks
Higher than 63% of US stocks
Higher than 51% of US stocks
Higher than 75% of US stocks
Higher than 73% of US stocks
Higher than 59% of US stocks
Higher than 74% of US stocks
Higher than 96% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kamada Ltd. has a market value of $464.6M and an enterprise value of $407.7M.
Revenue in the twelve months to 30 June 2026: $191.8M. The latest quarter grew 22.7% year on year.
Net income over the same four quarters: $22.3M, a 11.6% net margin.
Diluted earnings per share, trailing twelve months: $0.38.
Free cash flow in the twelve months to 30 June 2026: $26.3M.
Kamada Ltd. spent $14.4M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 21.2×; forward P/E: 14.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 8.68%, paying out 66% of earnings.
Kamada Ltd. employs 462 people — $415K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kamada Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kamada announced that it will participate in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London during November 2026.
Why it matters — KMDA watchers may note the company’s planned participation in two healthcare investor conferences.
Kamada announced the launch of two additional biosimilar products in Israel, expanding its portfolio commercialized in Israel and the MENA region. The company expects the portfolio to generate approximately $10 million in annual revenue in 2028 and approximately $20 million-$25 million by 2030.
Why it matters — The launches expand Kamada’s biosimilar offering, and the company provided revenue expectations for the growing portfolio.
Kamada presented its growth strategy and financial outlook, highlighting demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply, and potential acquisitions.
Why it matters — KMDA watchers would care because the presentation signals the company's growth direction and strategic focus within its plasma-derived product portfolio.
The CDC reported a significant year-over-year increase in U.S. rabies exposures and anti-rabies immunoglobulin use. Kamada confirmed it has sufficient KedRAB® supply, one of only two FDA-approved products in the U.S. market, to meet increased demand. Kamada Ltd. issued the announcement on September 17, 2026.
Why it matters — KMDA watchers would care because rising rabies exposure demand could increase utilization of Kamada's KedRAB, one of only two FDA-approved products in a U.S. market estimated at $200 million annually.
Kamada Ltd. announced that CEO Amir London will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, being held at the Lotte New York Palace Hotel. The announcement was made on September 10, 2026.
Why it matters — A KMDA watcher would care because the CEO's presentation at a major investment conference offers an opportunity for the company to update investors on its biopharmaceutical portfolio and specialty plasma-derived business.
The 3 Wall Street analysts covering Kamada Ltd. have a median 12-month price target of $14, with estimates ranging from $11 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Kamada Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kamada Ltd. 95 out of 100 across roughly 4,600 US stocks as at 9 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 9 Oct 2026, Kamada Ltd. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +78.6% from the last close, and Ticker Nerd's factor model ranks Kamada Ltd. 95 out of 100 as at 9 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kamada Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KMDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $15 over the next 12 months.
Kamada Ltd. returned +21.0% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics.
The most recent item we track (GlobeNewsWire, 19 Oct 2026): "Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026". Kamada announced that it will participate in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London during November 2026.
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics. Kamada Ltd. develops, manufactures, and markets a portfolio of marketed products for rare and serious conditions, with treatments used in areas such as lung disease, immunology, infectious disease prophylaxis, and critical care. The company’s commercial offering includes proprietary plasma-derived therapies and a distribution segment that markets additional biopharmaceutical products in selected international markets. Kamada Ltd. also operates manufacturing capabilities centered on plasma protein purification and sterile production, supporting its vertically integrated business model. Its products are sold through partners, distributors, hospitals, pharmacies, and healthcare organizations across multiple countries, making the company a specialized supplier within the global plasma therapeutics market.
462 employees · Israel · https://www.kamada.com
